ChromoGenics resolves on a rights issue of approximately SEK 39.7 million and changes the date for publication of the Q3 report
PRESS RELEASE THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN CHROMOGENICS AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW.The board of directors of ChromoGenics AB (publ) ("ChromoGenics" or the "Company") has today, on 6 October 2022,